Post-pandemic, there is an increasing demand for the CDMO-Biopharma relationship to focus on, dare we say it, “strategic partnering.” Strategic partnering – that industry buzz term used so loosely, with such frequency and abundance, that it edges close to a cliché. Yet, while it is true that the term is often overused and loosely defined when it’s precisely broken down, its basic definition holds the truest of post-pandemic lessons learned.